UsHERing in New Standards of Care on HER2+ and HER2-Low MBC

UsHERing in New Standards of Care on HER2+ and HER2-Low MBC

Chapter 1: Chapter 1: HER2+ Breast Cancer and HER2 Testing: Classifying the Spectrum of HER2 Expression

5 chapters
Play All
ReachMD Healthcare Image
Media formats available:
Program chapters
  • Overview

    Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or gene amplification is found in up to 20% of breast cancers, whereas 50% have low HER2 expression levels. The natural history of HER2-positive (HER2+) disease has been profoundly transformed by HER2-targeted agents and antibody-drug conjugates (ADCs). With the recent US Food and Drug Administration (FDA) approval of a novel HER2-directed ADC, trastuzumab deruxtecan (T-DXd), in both HER2+ and HER2-low metastatic breast cancer (MBC), potential treatment options have expanded for these patients.

    For practicing community clinicians, this evolution of HER2-directed therapy and targeting the full spectrum of HER2 expression threatens to add additional complexity in treatment selection and sequencing across lines of therapy. The increasing array of HER2-directed approaches challenges clinicians to stay abreast of clinical data and understand how to implement this evidence in daily practice. This session will assist clinicians in determining how these novel agents fit into treatment paradigms. This educational activity will address the implications of HER2-expression patterns on treatment selection and planning, explore the effective use of evolving therapeutic strategies, and review the latest clinical data on efficacy and safety as well as evidence-based guideline recommendations.

  • Target Audience

    This non-accredited session is designed for the interprofessional care team comprised of medical oncologists, pathologists, pulmonologists, oncology nurses, physician assistants, pharmacists, and other allied healthcare professionals involved in the active treatment and management of MBC across the spectrum of disease and HER2 expression patterns.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Integrate ADCs into treatment plans for patients with HER2+ MBC across lines of therapy based on evidence-based guideline recommendations and the latest clinical efficacy and safety data
    • Assess data on the evolving role of HER2-low expression status and how this emerging subtype may impact treatment decisions
    • Formulate mitigation strategies for identifying and managing treatment-related adverse events associated with HER2-directed antibody drug conjugates
    • Implement strategies to improve team-based care coordination and communication within the oncology care team, with other specialists, and with patients
  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Commercial Support

    Supported by an independent educational grant from Daiichi Sankyo Inc.

Facebook Comments

Facebook Comments


We’re glad to see you’re enjoying AXISMedEd…
but how about a more personalized experience?

Register for free